Although the Ros1 protein is not expressed in normal human lung tissue, ROS1 gene fusions with oncogenic activity are reported to occur in about 1–2% of NSCLC patients and are amenable to the development of molecular targeted therapies [39]. Here, ROS1 is linked to non-small cell lung carcinoma.